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Placental hypoxia is causally implicated in fetal
growth restriction and preeclampsia , with both oc-
curring more frequently at high altitude (>2700 m;
HA). The nuclear transcription factor hypoxia-in-
ducible factor (HIF) may facilitate placental oxygen
transport at HA by increasing erythropoiesis and
placental angiogenesis. We therefore investigated
HIF expression and its regulatory mechanisms in
placentas from normal pregnancies at high (3100
m), moderate (1600 m), and sea level (75 m) alti-
tudes. Moderate-altitude and sea level placentas did
not differ , but HIF-1 and the von Hippel-Lindau
tumor suppressor protein were overexpressed in
HA placentas. The ability of von Hippel-Lindau tu-
mor suppressor protein to form the E3 ubiquitin
protein ligase complex, required for HIF-1 degra-
dation, was unaltered in HA placentas. mRNA for
factor-inhibiting HIF, a negative modulator of
HIF-1 transactivation, was increased, but protein
levels were diminished. Elevated HIF-1 likely contrib-
uted to the significant increase we report in HIF-1
downstream target proteins, transforming growth
factor 3 in the placenta, and vascular endothelial
growth factor and erythropoietin in the maternal circu-
lation. These circulating markers and lowered birth to
placental weight ratios correlated with increased HIF-
1, thereby linking molecular and systemic physiolog-
ical data. The HA response to chronic hypoxia resem-
bles preeclampsia in several aspects, illustrating the
utility of the HA model in understanding placental
pathologies. (Am J Pathol 2007, 170:2171–2179; DOI:
10.2353/ajpath.2007.061185)
The influence of oxygen on fetoplacental development
and the role of hypoxia in causing or exacerbating patho-
logical conditions of pregnancy is a major focus of peri-
natal research. Despite the utility of animal and cell cul-
ture models using hypoxic stimuli, there is no in vivo
human model with which to compare the results of in vitro
and animal experimentation and no means to provide the
crucial link to healthy human pregnancy. To date, we do
not know whether artificial hypoxic stimuli mimic the
pathological conditions attributed to hypoxic stress in
vivo, nor can we distinguish the effects of hypoxia from
under- or overlying pathologies.
Residence at high altitude (2700 m) is associated
with reduced birth weight and an increased incidence of
pregnancy complications, in particular preeclampsia.1
The birth weight effect is independent of socioeconomic
status and other risk factors.2,3 High-altitude fetuses do
not attain their full genetic growth potential4 and thus
represent a natural model of fetal growth restriction. Pla-
cental hypoxia is often invoked as an underlying cause or
contributor to the development of preeclampsia and/or
fetal growth restriction.5,6 Thus the natural experiment of
high-altitude residence is a unique opportunity to exam-
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ine the pathways by which hypoxia, in the absence of
pathology, influences placental development and
function.
There is increased placental angiogenesis, a reduced
distance from the intervillous space to the fetal capillar-
ies,7 and increased maternal and fetal erythropoiesis at
high altitude that facilitate oxygen transport. Erythropoi-
esis and angiogenesis are regulated via the highly con-
served hypoxia-inducible factor (HIF) family of transcrip-
tion factors, implicating HIF as an element of critical
importance in placental adaptation to reduced oxygen
tension. The HIF family consists of heterodimers com-
posed of one of the three -subunits (HIF-1, HIF-2, or
HIF-3) and a -subunit known as the aryl hydrocarbon
nuclear translocator (ARNT). To become functional, the
-subunit must bind the -subunit, permitting the dimer to
bind to hypoxia response elements in the promoter re-
gions of hypoxia-sensitive genes. HIF regulation is com-
plex, involving a host of factors that can stabilize or
destabilize the -subunit and factors that can modify
transcriptional activity. Degradation of HIF-1 protein is
inhibited in hypoxia, and it accumulates in the nucleus
where, on binding to ARNT, it activates genes with hyp-
oxia response elements. Under normoxic conditions the
-subunit is rapidly ubiquitinated and degraded via the
proteosomal pathway,8 a process that requires interac-
tion with the von Hippel-Lindau tumor suppressor protein
(VHL).9 VHL in turn functions as the substrate recognition
component of an E3 ubiquitin protein ligase complex
comprising elongin B, elongin C, and Cullin-2 (the VHLcbc
complex).10 Neural precursor cell-expressed develop-
mentally down-regulated 8 (NEDD8) is a ubiquitin-like
molecule that binds to Cullin-2 (CUL2) in the VHLcbc
complex, and this association is required for VHL-medi-
ated HIF-1 degradation.11,12 Although there is evidence
for hypoxic induction of HIF-1 mRNA levels,13 the pre-
dominant pathways for HIF-1 regulation occur post-
translationally.14 During normoxia, factor-inhibiting HIF
(FIH) promotes hydroxylation of an asparagine residue in
the C-terminal transactivation domain of HIF-1, which in
turn inhibits the recruitment of transcriptional coactivator
proteins such as CREB binding protein/p300,15,16
thereby inhibiting HIF-1 transactivation activity. Thus,
under normoxic conditions HIF-1 is rapidly degraded
and/or inactivated.
A number of in vitro and in vivo studies have highlighted
the importance of HIF and its activity and degradation in
placental development and function.17–20 However,
these studies have focused on more acute low-oxygen
insults, largely in vitro, using assumptions about oxygen
exposures during established developmental windows or
in pathological pregnancy. We have shown that both high
altitude and preeclampsia are associated with placental
hypoxia and that HIF-regulated proteins are dysregulated
in preeclampsia.6,21 Two modes of HIF regulation are
independently controlled by oxygen availability, HIF-1
stability, and coactivator recruitment.14,16,22 We therefore
focused our studies on HIF-1 expression, the VHLcbc
complex, and FIH participation in posttranslational regu-
lation. We further tested the links between placental ex-
pression of HIF-1 and clinical parameters such as cir-
culating markers of hypoxia and pregnancy outcome,
relationships that have been tested in specific can-
cers23,24 but not in normal human pregnancy.
Materials and Methods
Participants
Informed consent was obtained in accordance with the
Institutional Review Boards/Ethics Committees of the par-
ticipating institutions. Participants included 11 women at
sea level (SL; Toronto, ON, Canada), 13 at 1600 m [mod-
erate altitude (MA); Denver, CO], and 15 at 3100 m [high
altitude (HA); Leadville, CO]. At MA and HA, we prospec-
tively evaluated circulating growth factors in women re-
cruited between weeks 9 and 15 of pregnancy. The SL
group comprised volunteers who served as normal
healthy controls in a prior study of preeclampsia in To-
ronto, ON, Canada.25 Women were excluded from study
if they had any chronic health conditions predisposing to
preeclampsia or if they used tobacco, alcohol, or pre-
scription or nonprescription (illicit) drugs other than pre-
natal vitamins. Women were excluded if they had an
abnormal oral glucose tolerance test or developed preg-
nancy complications. Participants residing at 1600 and
3100 m were included only if they had conceived, ges-
tated, and planned on remaining in the community until
after delivery. Women residing at 3100 m were excluded
if their work or other obligations required them to travel
routinely to lower altitudes.
All participants were enrolled in routine prenatal care
and had healthy, normal pregnancies resulting in single-
ton infants whose birth weights were appropriate for ges-
tational age. Participants did not differ in clinical at-
tributes (Table 1). Near-term arterial blood pressure was
normal in all women and did not differ between the three
sites. Gestational age was similar in all groups, but the
infants born at HA were of lower birth weight than infants
born at sea level or moderate altitude (Table 1).
Blood and Tissue Collection
Blood was drawn from the mothers’ antecubital vein at 2-
to 4-week intervals throughout pregnancy at MA and HA;
serum was separated by centrifugation and stored at
70°C for later analysis. Gestational age at the time the
blood sample was obtained was back-calculated using
the clinically assessed gestational age of the neonate.
Birth weight, gestational age, and laboratory values or
clinical observations relevant to the health of the mother
were abstracted from their clinical records.
Placentas were collected immediately after delivery
and placed in ice-cold phosphate-buffered saline. Villous
tissue from five separate regions of the villous core was
randomly excised and snap-frozen in liquid nitrogen. A
minimum of five random blocks of tissue were taken
through the entire thickness of the placenta for formalin
fixation and paraffin embedding.
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Circulating Markers of Hypoxia
Serial measurements of total serum vascular endothelial
growth factor (VEGF) were obtained by competitive ra-
dioimmunoassay as previously described.26 Inter- and
intra-assay coefficient of variation was 10%. Near-term
maternal circulating erythropoietin (EPO) was measured
by enzyme-linked immunosorbent assay (R&D Systems,
Minneapolis, MN) following the manufacturer’s recom-
mendations. Inter- and intra-assay coefficient of variation
was 3%.
RNA Isolation and Quantitative Real-Time
Polymerase Chain Reaction
Total RNA extracted from placental tissues was treated
with DNase to remove genomic DNA contamination. One
microgram of total RNA was reverse transcribed in a total
volume of 50 l using random hexamers (Applied Bio-
systems, Foster City, CA). The resulting templates (50 ng
of cDNA for our target genes and 5 ng for 18S) were
quantified by real-time polymerase chain reaction (PCR;
ABI Prism 7700). TaqMan probes and primers for human
HIF-1, ARNT, HIF-2, VHL, FIH, transforming growth
factor (TGF)-3, and ribosomal 18S were purchased from
Assays-on-Demand for human genes (Applied Biosys-
tems). For each probe, a dilution series determined the
efficiency of amplification of each primer/probe set, and
the relative quantification method was used.27 For the
relative quantitation, PCR signals were compared be-
tween groups after normalization using 18S as an in-
ternal reference. Briefly, relative expression was calcu-
lated as 2(Ct gene of interest  Ct 18S). Fold change was
calculated according to Livak et al.27
Western Blot Analysis
Western blot analyses were performed as previously de-
scribed.28 Primary antibodies were mouse monoclonal
anti-human HIF-1 (mgc3, 1:250; ABR-Affinity BioRe-
agents Incorporation, Golden, CO), mouse monoclonal
anti-human VHL (clone Ig33, 1:250; Oncogene, Cam-
bridge, MA), rabbit polyclonal anti-human CUL2 (1:250;
Neomarkers, Fremont, CA), rabbit polyclonal ARNT (1:
2000; Novus Biologicals, Littleton, CO), rabbit polyclonal
HIF-2 (1:1000; Novus Biologicals), rabbit polyclonal FIH
(1:250; Abcam, Cambridge, MA), and goat polyclonal
anti-human TGF3 (1:500; R&D Systems Inc.). Horserad-
ish peroxidase-conjugated secondary antibodies
(1:10,000) were rabbit anti-mouse for HIF-1 and VHL,
donkey anti-rabbit for CUL2 and ARNT, and donkey anti-
goat for TGF3 (Santa Cruz Biotechnology, Santa Cruz,
CA).
Immunoprecipitation
Immunoprecipitations were performed as previously de-
scribed.28 Five hundred micrograms of total protein ly-
sates was pre-cleared, antisera (1 g) were added, and
samples were incubated overnight. Immunoprecipitates
were then collected, subjected to sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis, and analyzed
by immunoblotting using mouse monoclonal anti-human
VHL (1:250), rabbit polyclonal antibody NEDD8 (1:500;
Alexis Biochemicals, San Diego, CA), or mouse mono-
clonal anti-human ubiquitin (1:500; Covance Research
Products, Berkeley, CA). A 1:10,000 dilution of anti-
mouse-Ig-horseradish peroxidase was used as second-
ary antibody.
Immunohistochemistry
Immunohistochemical analyses were performed as pre-
viously described.17 Placental tissues were fixed in buff-
ered formalin and embedded in paraffin. Before immu-
nohistochemical analysis, every 10th section was stained
with hematoxylin and eosin to assess the quality of the
tissue and select the most representative sections.
Mouse monoclonal antibodies against HIF1 and VHL
and rabbit polyclonal antibodies against CUL2 were all
used at 1:50 dilution. Secondary antibodies (1:300) were
either biotinylated goat anti-mouse or goat anti-rabbit
IgG. Control experiments were performed by replacing
the primary antibody with normal goat serum.
Statistical Analysis
Data are reported as mean  SEM. The maternal and
infant characteristics in Table 1 were compared using 2
or analysis of variance, as appropriate. For the time
course of changes in circulating VEGF, concentrations
Table 1. Maternal and Neonatal Characteristics
Participant data 75 m 1600 m 3100 m
n 11 13 15
Maternal age (years) 30.2  1.2 28.5  0.9 27.2  1.6
Primiparous (n) 6/11 13/13 15/15
Near-term systolic blood pressure (mm Hg) 112  7 113  8 112  12
Diastolic blood pressure (mm Hg) 68  6 73  8 74  8
Cesarean deliveries (n) 4/11 2/13 3/15
Gestational age (weeks) 39.1  1.1 39.2  0.3 39.8  1.7
Birth weight (g) 3395  300 3332  346 3066  260*†
Infant sex (male/female) 6/5 11/4 9/6
*P  0.05 SL versus high altitude.
†P  0.05 moderate versus high altitude.
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were compared between low- and high-altitude women
and across time during pregnancy using a linear mixed-
effects modeling approach as previously described.29
Relationships between variables were assessed using
linear regression. For comparison of data between mul-
tiple groups, we used Kruskal-Wallis one-way analysis of
variance with post hoc Dunn test. Statistical tests were
performed using Prism (GraphPad Software, San Diego,
CA) and StatView statistical software (StatView Software,
Cary, NC). Data are presented as mean  SEM and
reported as statistically significant when P  0.05.
Results
HIF-1 and VHL mRNA expression levels were signifi-
cantly increased in HA placentas relative to MA and SL
placentas (Figure 1A; HIF-1, 13.4-  5.3-fold HA versus
MA and SL, P  0.05; VHL, 16.1-  6.0-fold HA versus
MA and SL, P  0.05), whereas mRNA expression for
HIF-2 and ARNT were similar across all three altitudes
(Figure 1A). Western blots for HIF-1 and VHL were
consistent with the findings from quantitative real-time
PCR (Figure 1B, representative blots). Densitometric
analysis showed that the increased message was
associated with increased protein because both HIF-1
(2.26-  0.32-fold HA versus SL and MA, P  0.005) and
VHL (2.17-  0.30-fold HA versus SL and MA, P  0.05)
were elevated relative to SL and MA (Figure 1B). Consis-
tent with no change in message, ARNT protein levels
were similar across all altitudes (Figure 1B). In line with
the mRNA findings, HIF-2 protein expression was not
significantly altered between altitudes (data not shown)
and, therefore, was not further investigated.
We next examined components of the E3 ligase com-
plex and their interaction. CUL2 protein levels were sim-
ilar at all three altitudes (Figure 2A, top left blot), whereas
neddylated CUL2, identified as an 84-kd band, was re-
duced in HA placentas relative to SL and MA placentas
(0.35- 0.1-fold HA versus SL and MA, P 0.005; Figure
2A, top left blot and panel). The reduction in neddylated
CUL2 did not seem to translate into decreased binding of
the E3 ligase complex with VHL, because immunopre-
cipitation of VHL followed by Western blot for CUL2
showed no differences between the three altitudes (Fig-
ure 2A, top right blot).
To investigate whether HIF-1 is ubiquitinated to the
same degree between altitudes, HIF-1 was precipitated
from placental lysate with anti-HIF1 antibody, and im-
munoprecipitates were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis followed by
immunoblotting with an anti-ubiquitin antibody. This ex-
periment was repeated multiple times using all of the
samples available, and although variable, the results
showed that ubiquitination was either decreased or un-
changed at high altitude. Support for a decrease in ubiq-
uitination is provided by Figure 2A, right bottom blot:
Figure 1. mRNA and protein expression of HIF-related molecules in pla-
centas from different altitudes. A: Real-time PCR analysis for HIF-1, HIF-2 ,
ARNT, and VHL. B: Densitometric analysis of immunoblots for HIF-1,
ARNT, and VHL. Representative Western blots are inserted. *P  0.05.
Figure 2. VHLCBC complex interactions and immunolocalization of HIF-
related molecules in placenta at different altitudes. A: Left panel, top, West-
ern blot for Cullin-2 protein, detected at 76 kd, and neddylated Cullin-2
protein. Bottom: Densitometric analysis of neddylated Cullin-2, identified at
84 kd in Western blot (top). Right panel, top: Interaction between VHL and
Cullin2 identified by immunoprecipitation with VHL followed by immuno-
blotting with Cullin-2. Bottom: Immunoprecipitation of HIF-1 followed by
Western blotting with ubiquitin or HIF-1. B: Immunostaining for HIF-1,
VHL, and Cullin-2. Brown color depicts positive immunoreactivity. The
insets show greater magnification of the areas of interest. *P  0.05.
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Immunoprecipitated HIF-1, probed by Western blot for
HIF-1 was markedly increased at high altitude, which is
consistent with both decreased ubiquitination and the
protein results for HIF-1.
We also examined the spatial localization of HIF-1,
VHL, and CUL2 (Figure 2B). In HA placentas, HIF-1
immunostaining localized to the syncytiotrophoblast, to
the vascular endothelium, and to a lesser extent to the
mesenchymal tissue. Staining was virtually absent from
syncytium in MA placentas, although low positive immu-
noreactivity for HIF-1 was present in vascular endothe-
lium. VHL immunostaining localized to the syncytiotro-
phoblast of HA tissue, whereas no immunoreactivity was
present in the MA tissue. Strong positive immunoreactiv-
ity for CUL2 also localized to the syncytiotrophoblast but
did not differ between MA and HA.
Having established that HIF-1 and VHL are elevated
in HA placentas, that the E3 ligase complex binds VHL in
a manner similar to controls, and that ubiquitination was
decreased or unaltered, we continued the investigation
examining a mechanism that contributes to posttransla-
tional modification of HIF-1 activity. FIH is an asparag-
inyl hydroxylase enzyme known to impede HIF-1 gene
transcription via inhibition of recruitment of cofactors for
transcription. FIH mRNA was increased in HA versus SL
placentas (Figure 3A, left panel), but protein was mark-
edly decreased (Figure 3A, right panel). MA placentas
were similar to SL placentas (data not shown). Increased
HIF-1 protein production in conjunction with decreased
FIH would be expected to lead to greater levels of HIF-
1-dependent gene transactivation relative to sea level.
We therefore tested placental expression of TGF3,
which is regulated via HIF-1 and plays a key role in early
placental development.17,30 To extend these placental
findings to maternal physiology, we also examined two
other well-known HIF-1-mediated gene products, EPO
and VEGF, in the maternal circulation. Placental mRNA
and protein for TGF3 (Figure 3B, left and right panel,
respectively) more than doubled at high altitude relative
to sea level, whereas moderate altitude did not differ from
sea level (data not shown). EPO (26.0  1.2 mIU at HA,
21.8  1.0 mIU at MA, P  0.05) and total VEGF (8.6 
3.1 at HA versus 5.6  3.1 ng/ml at MA, P  0.01)
concentrations were significantly increased at high alti-
tude in the last serum sample obtained before delivery.
We have previously shown increased mRNA for total
VEGF in these same placental samples.21 However, be-
cause the placenta at term is a snapshot in time and
because human placental samples cannot be taken be-
fore delivery, we measured maternal circulating total
VEGF throughout pregnancy to see at what time point
chronic placental hypoxia might translate into increased
serum concentrations of total VEGF in HA mothers. Total
VEGF was significantly increased at high altitude from
week 20 of gestation onward (Figure 4A). That the pla-
Figure 3. mRNA and protein expression of FIH (A) and TGF3 (B) in
placentas from different altitudes. Expression levels were determined by
real-time PCR (left panels) and Western blot (right panels) analysis. *P 
0.05.
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Figure 4. Circulating VEGF levels and correlations with birth weights at
different altitudes. A: Total VEGF concentrations during pregnancy at differ-
ent altitudes. MA (open circles, hatched line) and HA (closed circles, solid
line). The symbols are the mean and SD of the VEGF concentration measured
at a particular time point, whereas the lines represent the best-fit regression
equations of the time course of change in VEGF (MA, y  0.004x2  0.130x
 4.493, r2  0.83; HA, y  0.005x2  0.097x  5.369, r2  0.86). VEGF
concentrations were significantly elevated from week 20 onward at high
versus moderate altitude. B: Maternal blood VEGF concentrations measured
at 14.7  1.3 weeks (range, 12 to 18 weeks) were inversely correlated with
birth weight at high altitude (y  3629.62  109.41x, r2  0.35, P  0.05). C:
VEGF concentration in the last maternal blood sample obtained before
delivery (range, 34 to 39 weeks; mean, 35.7  1.2) was inversely correlated
with birth weight at high altitude (y 3673.28 65.15x, r2 0.28, P 0.05).
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centa was the source of this increased VEGF is sup-
ported by samples collected within 24 hours of delivery;
these values (1.4  0.5 ng/ml at MA, 1.3  0.6 ng/ml at
HA, P  NS) did not differ from those obtained more than
3 months postpartum in the same women (1.0  0.4
ng/ml at MA, 1.0  0.3 ng/ml at HA, P  NS). There was
thus no effect of altitude on circulating VEGF in the non-
pregnant condition. We also found that circulating VEGF
was negatively associated with birth weight both at the
time of initial blood sampling in the late first/early second
trimester and in the last value obtained before delivery at
high altitude (Figure 4, B and C). There was no relation-
ship between VEGF and birth weight at moderate altitude
(data not shown). Placental HIF-1 protein, across both
altitudes, was positively associated with maternal near-
term circulating VEGF and erythropoietin concentrations
(Figure 5, A and B) and negatively associated with the
birth-to-placental weight ratio (Figure 5C). This last cor-
relation indicates that infants whose body size is small
relative to their placental size have greater placental
HIF-1 expression and are perhaps exposed to greater
hypoxia or are more responsive to a given oxygen
tension.
Discussion
An intricate balance between HIF-1 and its regulatory
molecules was revealed within the high-altitude model.
The 10- and 20-fold increases in HIF-1 and VHL mRNA,
respectively, were associated with a doubling of protein
levels. FIH showed a fivefold increase in mRNA but re-
duced protein levels. VHL binding to CUL2 was un-
changed, and HIF-1 ubiquitination was similar or lower
at high altitude. These alterations in HIF-1 and its regu-
latory machinery translated into significant increases in
HIF-1 downstream targets (TGF3, EPO, and VEGF) in
the placenta and maternal circulation. This may be due to
greater placental HIF-1 expression and decreased in-
hibition of HIF-1 transactivation. To our knowledge,
these data are the first to directly correlate placental
molecular findings with circulating growth factors during
pregnancy and with pregnancy outcome.
Apart from one report, all of the high-altitude data point
to excess HIF-1 expression and activity in the high-
altitude placenta. The other report measured HIF-1 activ-
ity using an enzyme-linked immunosorbent assay, which
showed no differences, and concluded that the placen-
tas were well adapted.31 However, global patterns of
gene expression are similar in high-altitude versus in vitro
low-oxygen treatment.21 A number of HIF-regulated
genes clustered with greater expression levels in both
hypoxic conditions relative to control.21 Increased capil-
lary density and enhanced ballooning of the capillaries
within the tertiary villi are characteristics of placental ad-
aptation at high altitude.32,33 Placental erythropoietin re-
ceptor is increased, and at least four gene products
known to be HIF-regulated and produced by the placenta
(VEGF, EPO, sFLT-1, and endothelin) are elevated in
the placenta and/or maternal circulation at high
altitude.25,34,35
The -subunit of HIF-1 is constitutively produced, and
our data, like that from most other cell and tissue sys-
tems, show no change in ARNT mRNA or protein with
hypoxia.14,36 The decrement in oxygen tension in the
blood entering the intervillous space at an altitude of
3100 m is 20%.7 Because intervillous oxygen tension is
already quite low near term (40 mm Hg or approximately
6%),37 the altitude-associated decrement to approxi-
mately 4 to 5% is close to what is used in cell and organ
culture to mimic placental “hypoxia.” That such subtle
differences can translate into differences in expression of
HIF-1 and its regulatory molecules is supported by prior
work from our laboratories showing that HIF-regulatory
proteins such as prolyl hydroxylases respond to changes
in oxygen encompassing 2 to 8%.20 This same subtlety is
now well documented in human placental development:
HIF-1 mRNA and protein expression are elevated early
in gestation when oxygen tension is low (2 to 3%) and
decline with the onset of higher oxygen tension (8%) in
the late first trimester.38 Because FIH is regulated by
oxygen independent of HIF1 stability,16 elevated tran-
scripts suggest either that that this enzyme is capable of
sensing the lowered oxygen present in the high-altitude
placenta or that factors as yet unidentified inhibit trans-
lation under conditions of hypoxia. Of particular impor-
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Figure 5. Correlations of placental HIF-1 protein with circulating hypoxia
markers and birth/placental weights. A and B: Placental HIF-1 protein in HA
placenta correlates with both circulating markers of hypoxia, VEGF (A, y 
2.297x  4.627, r2  0.33, P  0.05) and erythropoietin (B, y  2.01x 
19.66, r2  0.33, P  0.05) across high and moderate altitudes. C: HIF-1
protein correlated with the birth to placental weight ratio across both alti-
tudes (y  7.72  1.20x, r2  0.45, P  0.05).
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tance is that the decreased FIH protein levels likely con-
tributed to the increased downstream placental gene
products we examined, including TGF3, which is known
to be directly regulated by HIF-1.20,30
We recognize that in many models, hypoxia does not
increase HIF-1 mRNA but operates at the level of pro-
tein stabilization. Conversely, in some models, sustained
increase in HIF-1 mRNA is related to mRNA stabiliza-
tion.36 Our data on these term samples are consistent
with those obtained in organ culture from first trimester
placentas.17 This suggests that in vivo, the trophoblast
can maintain higher levels of HIF-1 mRNA expression,
just as is observed in some cancer cells.39,40 However,
we cannot exclude that other mechanisms unrelated to
hypoxia such as prostanoids,41 norepinephrine,42 and
cytokines43 may contribute to the higher levels of HIF-1
reported here.
The increase in VHL at HA begs the question of why
HIF-1 protein remained elevated. An increase in VHL
protein does not reflect the amount of VHL that is func-
tionally capable of binding HIF-1 and targeting it for
degradation. Leaving aside potential modification of the
binding dynamics between the VHL complex and HIF-1,
our data suggest that similar amounts of HIF-1 would be
bound and targeted for degradation. Thus an increase in
HIF-1 protein, uncompensated by an equivalent in-
crease in the functional VHLcbc complex would lead to an
increase in HIF1 protein and gene activation, which is
what we observed. With respect to the question of VHL
complex and HIF-1 binding dynamics, there is strong
evidence to support that the action of prolyl hydroxy-
lases, required for VHLcbc recognition of the HIF-1-
subunit, is reduced under conditions of hypoxia.44–46
Future studies are warranted to examine the expression
of these enzymes in placentas from high-altitude preg-
nancies. The results on HIF-1 ubiquitination showed that
it was decreased or unchanged at high altitude. How-
ever, the literature and the balance of the other data
acquired, especially the reduction in neddylated CUL2,
which is required in vitro for full ubiquitin ligase activity of
the VHLCBC complex,12 would support that decreased
ubiquitination was present at high altitude.
The observation that VHL expression is elevated in
conditions of chronic hypoxia is in agreement with our
recent observation showing increased VHL in early ges-
tation20 and with other in vitro studies showing oxygen-
dependent changes in VHL expression both in cell lines
and villous explants.47,48 In addition, the elevated level of
VHL may contribute to other features noted in the high-
altitude placenta, eg, cytotrophoblast proliferation,49 be-
cause VHL plays a role in regulating a variety of cellular
events including cell proliferation and extracellular matrix
assembly.50,51 The finding of less neddylated CUL2 in
HA placentas is also consistent with the prior literature.
As noted above, NEDD8 conjugation to CUL2 is required
for full ubiquitin ligase activity of the VHLCBC complex12
but is not essential for VHLCBC complex formation.52 Ned-
dylated CUL2 first appears in human placentas during
the developmental window in which intervillous oxygen
tension rises.20 Its reduction in the present report is con-
sistent with lowered oxygen tension.
We examined circulating total VEGF as a serial marker
of placental hypoxia during pregnancy. Free VEGF is
virtually absent in human pregnancy, and hence the total
(bound) VEGF that we measured in the circulation is
unlikely to have significant biological function. It may
exert paracrine effects within the placenta before binding
with its soluble receptor sFlt-1, including vasodila-
tion.53,54 Our measures immediately postpartum and 3
months after delivery indicate that the elevated total
VEGF in human pregnancy is of placental origin. Placen-
tal HIF protein was positively correlated with near-term
maternal circulating VEGF and erythropoietin, supporting
the idea that placental HIF activation can measurably
impact on maternal physiology. In turn, excess VEGF in
the maternal circulation was associated with lower birth
weight. The opposite is found at mid-gestation at sea
level: greater total VEGF was correlated with greater birth
weight.55 Wheeler et al55 speculated that the correlations
earlier in pregnancy at sea level may reflect maternal
cardiovascular adaptation to pregnancy. If this were the
case, it would not necessarily be surprising to find a
negative relationship at high altitude. Maternal physiolog-
ical changes at high altitude are intermediate between
normal and preeclamptic pregnancy at sea level.56
Finally, our findings may provide the opportunity to
refine our understanding of pregnancy pathologies. Dys-
regulation of the HIF system is implicated in preeclamptic
pregnancies.6,17,57,58 The increase in HIF-1 reported
here is similar to or even greater than the rise reported in
preeclampsia, but it differs in that we see no increase in
HIF-2.59 HIF-2 is implicated in oxidative stress,60
which is increased in preeclamptic placentas61 but de-
creased in the high-altitude model.62 We have shown that
there are similar patterns of gene expression in high-
altitude and preeclamptic placentas. However, the pre-
eclamptic placentas had greater increases in the HIF-
regulated genes VEGF, TGF3, and ceruloplasmin than
those from high altitude.21 These data suggest that for a
given level of HIF-1, transactivation may be increased in
preeclampsia. Hence, posttranscriptional mechanisms
would bear closer inspection in the pathology of pre-
eclamptic pregnancies.
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